FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281739883> ?p ?o ?g. }

• W4281739883 endingPage "109338" @default.
• W4281739883 startingPage "109338" @default.
• W4281739883 abstract "Background: Patients with diabetes mellitus (DM) are at increased risk for intubation, death, and other complications from COVID-19. However, the importance of a patient’s glycemic control preceding the COVID-19 infection is less well understood. Method: From March to November 2020, data from adult patients with confirmed COVID-19 admitted to Rush University System for Health (RUSH) was studied. Patients with both a pre-existing history of diabetes mellitus (DM) and a hemoglobin A1c (HbA1c) measurement during their hospitalization were included. Based on their HbA1c, patients were then divided into 4 groups: adequate glycemic control (≤ 6.5), mild elevation (6.5 – 7.4), intermediate elevation (7.5 – 8.4), and severe elevation (≥ 8.5). Multivariable logistic regression, adjusted for age, body mass index, and pre-existing history of atrial fibrillation, coronary artery disease, hypertension, and chronic obstructive pulmonary disorder, was performed with glycemic control group as a predictor for 60-day mortality and severe COVID-19, which was a composite of 60-day mortality or requiring the intensive care unit, non-invasive positive pressure ventilation, or mechanical ventilation. Major adverse cardiac events (MACE) were defined as nonfatal myocardial injury, nonfatal stroke, or cardiovascular death. Results: Of the 1682 patients admitted, 774 had pre-existing DM, and 534 had HbA1c measurement during their hospitalization. The median HbA1c value was 8.0% (interquartile range 6.6% – 9.9%). In our entire cohort, 75 (14.0%) and 280 (52.4%) patients suffered 60-day mortality and severe COVID-19 infection, respectively. When adjusting for baseline characteristics and comorbidities, patients with mild (adjusted odds ratio [aOR] 2.39 [CI 1.04 – 5.83]; p < 0.05) and intermediate (aOR 3.59 [CI 1.49 – 9.12]; p < 0.01) HbA1c elevation were at increased risk of 60-day mortality compared to those with adequate glycemic control; no statistically significant difference was present in those with severe elevation (aOR 2.19 [CI 0.95 – 5.44]; p = 0.08). Furthermore, only the mild HbA1c elevation group was at increased risk for severe COVID-19 infection (aOR 1.88 [CI 1.06 – 3.38]; p < 0.05). Those with intermediate (aOR 1.77 [CI 0.94 – 3.33]; p = 0.08) or severe (aOR 1.57 [CI 0.92 – 2.70]; p = 0.10) HbA1c elevation were not at higher risk for severe COVID-19 infection. When comparing other 60-day outcomes, there was no difference between the glycemic groups in MACE, life-threatening arrhythmia, deep venous thrombosis, acute renal failure requiring renal replacement therapy, and pulmonary embolism (Table 1).Table 160-Day Outcomes by Level of Glycemic Control.Adequate Glycemic ControlMild ElevationIntermediate ElevationSevere Elevationp-valuen10611279224MACE (%)7(6.6)7(6.2)5(6.3)9(4.0)0.697Life Threatening Arrhythmia (%)6(5.7)10(8.9)7(8.9)15(6.7)0.737Deep Venous Thrombosis (%)4(3.8)4(3.6)3(3.8)12(5.4)0.841Renal Replacement Therapy (%)7(6.6)11(9.8)11(13.9)21(9.4)0.420Pulmonary Embolism (%)3(2.8)5(4.5)7(8.9)9(4.0)0.241MACE = major adverse cardiac events. Open table in a new tab MACE = major adverse cardiac events. Discussion: In our cohort, patients with DM with an HbA1c of 6.5 – 8.4 were at increased risk of 60-day mortality, while those with an HbA1c of 6.5 – 7.4 were at an increased risk of severe COVID-19 infection." @default.
• W4281739883 created "2022-06-13" @default.
• W4281739883 creator A5026306315 @default.
• W4281739883 creator A5044351769 @default.
• W4281739883 creator A5049006916 @default.
• W4281739883 creator A5055641712 @default.
• W4281739883 creator A5068923930 @default.
• W4281739883 creator A5074847510 @default.
• W4281739883 creator A5085139358 @default.
• W4281739883 creator A5091870255 @default.
• W4281739883 creator A5015523490 @default.
• W4281739883 date "2022-04-01" @default.
• W4281739883 modified "2023-10-18" @default.
• W4281739883 title "IDF21-0311 Pre-Admission, Diabetic Glycemic Control on 60-Day Mortality and Major Adverse Cardiovascular Events from COVID-19" @default.
• W4281739883 doi "https://doi.org/10.1016/j.diabres.2022.109338" @default.
• W4281739883 hasPublicationYear "2022" @default.
• W4281739883 type Work @default.
• W4281739883 citedByCount "0" @default.
• W4281739883 crossrefType "journal-article" @default.
• W4281739883 hasAuthorship W4281739883A5015523490 @default.
• W4281739883 hasAuthorship W4281739883A5026306315 @default.
• W4281739883 hasAuthorship W4281739883A5044351769 @default.
• W4281739883 hasAuthorship W4281739883A5049006916 @default.
• W4281739883 hasAuthorship W4281739883A5055641712 @default.
• W4281739883 hasAuthorship W4281739883A5068923930 @default.
• W4281739883 hasAuthorship W4281739883A5074847510 @default.
• W4281739883 hasAuthorship W4281739883A5085139358 @default.
• W4281739883 hasAuthorship W4281739883A5091870255 @default.
• W4281739883 hasBestOaLocation W42817398831 @default.
• W4281739883 hasConcept C119060515 @default.
• W4281739883 hasConcept C126322002 @default.
• W4281739883 hasConcept C134018914 @default.
• W4281739883 hasConcept C164705383 @default.
• W4281739883 hasConcept C2776376669 @default.
• W4281739883 hasConcept C2776780178 @default.
• W4281739883 hasConcept C2778213512 @default.
• W4281739883 hasConcept C2779161974 @default.
• W4281739883 hasConcept C2779306644 @default.
• W4281739883 hasConcept C2780221984 @default.
• W4281739883 hasConcept C2780400711 @default.
• W4281739883 hasConcept C2780473172 @default.
• W4281739883 hasConcept C500558357 @default.
• W4281739883 hasConcept C555293320 @default.
• W4281739883 hasConcept C71924100 @default.
• W4281739883 hasConceptScore W4281739883C119060515 @default.
• W4281739883 hasConceptScore W4281739883C126322002 @default.
• W4281739883 hasConceptScore W4281739883C134018914 @default.
• W4281739883 hasConceptScore W4281739883C164705383 @default.
• W4281739883 hasConceptScore W4281739883C2776376669 @default.
• W4281739883 hasConceptScore W4281739883C2776780178 @default.
• W4281739883 hasConceptScore W4281739883C2778213512 @default.
• W4281739883 hasConceptScore W4281739883C2779161974 @default.
• W4281739883 hasConceptScore W4281739883C2779306644 @default.
• W4281739883 hasConceptScore W4281739883C2780221984 @default.
• W4281739883 hasConceptScore W4281739883C2780400711 @default.
• W4281739883 hasConceptScore W4281739883C2780473172 @default.
• W4281739883 hasConceptScore W4281739883C500558357 @default.
• W4281739883 hasConceptScore W4281739883C555293320 @default.
• W4281739883 hasConceptScore W4281739883C71924100 @default.
• W4281739883 hasLocation W42817398831 @default.
• W4281739883 hasLocation W42817398832 @default.
• W4281739883 hasOpenAccess W4281739883 @default.
• W4281739883 hasPrimaryLocation W42817398831 @default.
• W4281739883 hasRelatedWork W1994233110 @default.
• W4281739883 hasRelatedWork W2017505888 @default.
• W4281739883 hasRelatedWork W2145553842 @default.
• W4281739883 hasRelatedWork W2399063111 @default.
• W4281739883 hasRelatedWork W2888906357 @default.
• W4281739883 hasRelatedWork W2890586653 @default.
• W4281739883 hasRelatedWork W2971392718 @default.
• W4281739883 hasRelatedWork W2981847246 @default.
• W4281739883 hasRelatedWork W3091935110 @default.
• W4281739883 hasRelatedWork W3093656048 @default.
• W4281739883 hasVolume "186" @default.
• W4281739883 isParatext "false" @default.
• W4281739883 isRetracted "false" @default.
• W4281739883 workType "article" @default.